May
5
2020
On demand

Stable AAV producer cell lines: elevating vector manufacturing

Recombinant adeno-associated virus (rAAV) has shown great promise as a suitable vector for in vivo gene therapies. Consequently, there is a rapidly increasing demand for rAAV production and robust and scalable manufacturing processes.

Currently established rAAV production methods rely on transient transfection of plasmid DNA or transduction of the producing cell with helper viruses.

Using an innovative approach based on its proprietary serum-free suspension cell line, CEVEC has developed a production system that uses rAAV producer cells, which have stably integrated into their genome all the elements required for rAAV assembly as well as the ITR-flanked transgene. For rAAV production, no further transfection steps or helper viruses are required.

The platform can be adapted to various serotypes and transgenes and has been designed for scalable production in stirred tank bioreactors. Data from production runs at different scales will be presented.

Attendees find out how to:

  • Address the production gap for AAV gene therapy vectors
  • Deliver consistent quality across batches of AAV vector through removal of the need for a transfection step
  • Achieve reliable AAV production upon induction of producer cells
  • Optimize scale-up plasmid- and helper virus-free production of AAV vectors in stirred tank bioreactors

Silke Wissing
Chief Scientific Officer

SPEAKERS

Silke Wissing
Chief Scientific Officer

You might also like

Thinking translational: Things to consider in CAR T cell research workflows

S Rösch, PhD
Saskia Rösch, PhD
Saskia Rösch, PhD
Global Product Manager at Miltenyi Biotec
22 Jun 2022
35
Days
5
Hrs
22
Min
Register

Accelerating cell therapy discovery & development with non-viral gene...

D Hermanson
X Patrinostro
David Hermanson
David Hermanson
Senior Manager of R&D Applications, Cell and Gene Therapy at Bio-techne
Xiaobai Patrinostro
Xiaobai Patrinostro
Manager of Genome Engineering Services, Cell and Gene Therapy at Bio-techne
16 Jun 2022
28
Days
13
Hrs
22
Min
Register

Optimizing mRNA purification conditions by using a Design of Experiments...

J England
Jenny England
Jenny England
Application Scientist and Innovation Leader at Thermo Fisher Scientific
14 Jun 2022
27
Days
5
Hrs
22
Min
Register

Taking a right first-time approach to optimize end-to-end viral vector...

H Lesch
J Depollier
Hanna Lesch
Hanna Lesch
Chief Technology Officer at Exothera
Julien Depollier
Julien Depollier
Business Director, Americas at Polyplus-transfection
9 Jun 2022
22
Days
5
Hrs
22
Min
Register

Applying an HPLC analytical platform for mRNA process monitoring

N Pavlin
Nejc Pavlin
Nejc Pavlin
Project Manager in Process Analytics Development at BIA Separations
7 Jun 2022
20
Days
5
Hrs
22
Min
Register